• Kura Oncology posted a 2Q 2026 net loss of USD 68.33 million, or USD 0.77 a share, versus a USD 66.12 million loss.
• Total revenue rose to USD 20.87 million, driven by USD 9.1 million in net product revenue from KOMZIFTI’s launch.
• SG&A expenses climbed to USD 31.75 million from USD 25.17 million, while R&D spending edged down to USD 61.89 million.
• KOMZIFTI net product revenue rose 57% from 1Q to USD 9.1 million; new patient starts increased 35% to about 115.
• Cash, cash equivalents and short-term investments were USD 519.03 million; management expects runway through a pivotal KOMET-017 readout in 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608121602PRIMZONEFULLFEED9808833) on August 12, 2026, and is solely responsible for the information contained therein.